These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26765576)

  • 21. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
    Ahrén B
    Acta Physiol Scand; 2001 Feb; 171(2):161-7. PubMed ID: 11350276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
    Al Jobori H; Daniele G; Adams J; Cersosimo E; Triplitt C; DeFronzo RA; Abdul-Ghani M
    Diabetes Obes Metab; 2017 Jun; 19(6):809-813. PubMed ID: 28128510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study.
    Melmer A; Kempf P; Lunger L; Pieber TR; Mader JK; Stettler C; Tilg H; Ebenbichler CF; Laimer M
    Diabetes Obes Metab; 2018 Nov; 20(11):2685-2689. PubMed ID: 29923299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus.
    Al Jobori H; Daniele G; Adams J; Cersosimo E; Solis-Herrera C; Triplitt C; DeFronzo RA; Abdul-Ghani M
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1402-1407. PubMed ID: 29342295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus.
    Vaag AA; Beck-Nielsen H
    Acta Endocrinol (Copenh); 1992 Oct; 127(4):344-50. PubMed ID: 1449046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
    Alatrach M; Laichuthai N; Martinez R; Agyin C; Ali AM; Al-Jobori H; Lavynenko O; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
    Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
    Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
    Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
    Blachère JC; Pérusse F; Bukowiecki LJ
    Metabolism; 2001 Aug; 50(8):945-51. PubMed ID: 11474483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
    Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
    Joannides CN; Mangiafico SP; Waters MF; Lamont BJ; Andrikopoulos S
    Diabetes Obes Metab; 2017 Aug; 19(8):1135-1146. PubMed ID: 28244693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects.
    Qvigstad E; Mostad IL; Bjerve KS; Grill VE
    Am J Physiol Endocrinol Metab; 2003 Jan; 284(1):E129-37. PubMed ID: 12485810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thiazolidinediones improve beta-cell function in type 2 diabetic patients.
    Gastaldelli A; Ferrannini E; Miyazaki Y; Matsuda M; Mari A; DeFronzo RA
    Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E871-83. PubMed ID: 17106061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
    Henry RR; Dandona P; Pettus J; Mudaliar S; Xu J; Hansen L
    Diabetes Obes Metab; 2017 Jun; 19(6):814-821. PubMed ID: 28098426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Acipimox on the metabolism of free fatty acids and very low lipoprotein triglyceride.
    Hannah JS; Bodkin NL; Paidi MS; Anh-Le N; Howard BV; Hansen BC
    Acta Diabetol; 1995 Dec; 32(4):279-83. PubMed ID: 8750769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of forearm immobilization and acipimox administration on muscle amino acid metabolism and insulin sensitivity in healthy, young volunteers.
    Dirks ML; Jameson TSO; Andrews RC; Dunlop MV; Abdelrahman DR; Murton AJ; Wall BT; Stephens FB
    Am J Physiol Endocrinol Metab; 2024 Mar; 326(3):E277-E289. PubMed ID: 38231001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.